Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

the eye, is the 4th leading cause of blindness and often affects patients under the age of 40, but the disease remains frequently mistreated," commented Dr. Rosenbaum. "Uveitis has many causes and experts often disagree about what constitutes successful treatment. Accordingly, no pharmaceutical company previously has attempted to demonstrate that an oral medication can successfully treat uveitis, and there are currently no FDA-approved oral medications for this condition. Treating physicians often prescribe corticosteroids, which are burdened with a variety of serious systemic side effects when given orally. Even if applied as drops to the eye, corticosteroids can cause cataract formation and glaucoma. Based on the results of the LUMINATE trial program, LX211 appears to offer a therapeutic and safety profile that would meet the critical need for an oral medication for uveitis. LX211 is not a corticosteroid, but allows the reduced use of corticosteroids like prednisone, which in turn reduces the serious side-effects associated with those drugs."

Dr. Rosenbaum noted that a poster presentation at ARVO from a survey of U.S. ophthalmologists and rheumatologists from 27 states, presented by researchers from the Wilmer Eye Institute of Johns Hopkins University, Baltimore, found that the dose of oral corticosteroids used commonly to keep chronic inflammation within the eye under control is in the range of 25 mg/day. This compares to a recommended chronic dose by the uveitis community of 10 mg/day or less. Of additional note, patients enrolled in the LX211-02 protocol, which evaluated the use of LX-211 in subjects with treated but quiescent disease, received doses of corticosteroids that were more than 50% higher than this recommendation. It is well documented that systemic steroids at doses above 10 mg/day cause a myriad of adverse effects, such as osteoporosis, resulting in increased risk for hip or spinal fractures, and metabolic disturbances including obesity, h
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. The first DFG research centers to be funded for another 4 years
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... that it has been granted a patent by ... its unique delivery system for delivering its "original" ... for the treatment of diseases with an inflammatory ...
(Date:9/17/2014)... Cary, N.C. (PRWEB) September 17, 2014 ... solutions that advances science and healthcare, has renewed its ... term. , As part of the agreement, Personify will ... with a sustained emphasis on recruitment analytics, including time-to-fill, ... decision to renew our agreement with Personify was based ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... France, October 13 ,Following fulfillment of all the ... all outstanding shares of Satisloh Holding,AG, the world ... and markets antireflective coating units and surfacing,machines, as ... million in revenue in 2007 and employs more ...
... 12 Mentice, Inc., a,leading developer and ... systems and Education Management Solutions, Inc. (EMS), ... software solutions, today,announced at the Transcatheter Cardiovascular ... that enables Mentice to market,MenticeSIM(TM) as a ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... with the NASDAQ Listing Qualifications Panel to present ... 4450(b)(1)(A),which requires a minimum market value of listed ... Letter from The NASDAQ Stock Market LLC,on October ...
Cached Biology Technology:Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 2Mentice, Inc. and Education Management Solutions, Inc. Form OEM Partnership 3Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 2Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter 3
(Date:9/17/2014)... learned a great deal about complex social behavior by ... something to teach too. , With their unusually large ... parrots live in a complex social environment---not merely in ... or ants, but in a dynamic setting of alliances ... intelligent mammals: dolphins, whales, primates, and social carnivores, like ...
(Date:9/16/2014)... September, 2014)More than $100 trillion in cumulative public ... carbon dioxide (CO2)a 40 percent reduction of urban ... the world expands public transportation, walking and cycling ... by the University of California, Davis, and the ... , Further, an estimated 1.4 million early deaths ...
(Date:9/16/2014)... Ore. -- Each tree species has its own bacterial ... and colleagues from other institutions who studied the genetic ... on a Panamanian island. , "This study demonstrates for ... families and with different ecological strategies possess very different ... W. Kembel, a former postdoctoral researcher in the UO,s ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2
... up a large fraction of known plant viruses and ... to crop plants throughout the world. New details of ... by scientists using a variety of sophisticated imaging techniques ... and collaborating institutions. These findings, just published in ...
... GSK company focused on discovering and developing small molecule ... 2 Diabetes, announced today that it published a new ... and its potential to treat diseases of aging such ... heart disease. Entitled "SIRTUINS Novel Therapeutic Targets ...
... articles that will be published in the October 2008 ... Community Ecology: A Hybrid Beast with a Molecular Master. ... Thomas D. Bruns. , DNA-based techniques have in recent ... the first time. Results show extremely high diversity and ...
Cached Biology News:Structures of important plant viruses determined 2Structures of important plant viruses determined 3Sirtris' review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery 2BioScience tip sheet, October 2008 2BioScience tip sheet, October 2008 3
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
LTBP-1 (E-20)...
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Biology Products: